Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Insight, 2019 with Analysis by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com

DUBLIN--()--The "Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

The report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Juvenile Macular Degeneration (Stargardt Disease) development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

  • The report provides a snapshot of the pipeline development for Juvenile Macular Degeneration (Stargardt Disease)
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Juvenile Macular Degeneration (Stargardt Disease)
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Juvenile Macular Degeneration (Stargardt Disease)
  • The report also covers the dormant and discontinued pipeline projects related to Juvenile Macular Degeneration (Stargardt Disease)

Reasons to Buy

  • Establish comprehensive understanding of the pipeline activity across this Juvenile Macular Degeneration (Stargardt Disease) to formulate effective R&D strategies
  • Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
  • Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Juvenile Macular Degeneration (Stargardt Disease) therapeutics
  • Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Key Topics Covered

1. Report Introduction

2. Juvenile Macular Degeneration (Stargardt Disease) Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Juvenile Macular Degeneration (Stargardt Disease)

4. Comparative Analysis

5. Products in Clinical Stage

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

  • Product Description
  • Research and Development
  • Product Development Activities

Companies Mentioned

  • Astellas Pharma
  • Acucela Inc.
  • Alkeus Pharmaceuticals Inc.
  • Katairo
  • Astellas Pharma Inc.
  • Copernicus Therapeutics Inc.
  • Grupo Ferrer Internacional S.A.
  • Iris Pharma

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/18s697

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Optical Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Optical Disorders Drugs